M&A Deal Summary

Myriad Acquires Counsyl

On May 28, 2018, Myriad acquired life science company Counsyl for 375M USD

Acquisition Highlights
  • This is Myriad’s 4th transaction in the Life Science sector.
  • This is Myriad’s largest (disclosed) transaction.
  • This is Myriad’s 4th transaction in the United States.
  • This is Myriad’s 2nd transaction in California.

M&A Deal Summary
Date 2018-05-28
Target Counsyl
Sector Life Science
Buyer(s) Myriad
Deal Type Add-on Acquisition
Deal Value 375M USD
Advisor(s) Piper Jaffray Companies (Financial)
Cooley (Legal)

Target

Counsyl

South San Francisco, California, United States
Counsyl, Inc. is a provider of an actionable information that guides women and their families in making critical and timely health decisions. Counsyl operates a high-complexity clinical laboratory that offers the Foresight™ Carrier Screen, Prelude™ Prenatal Screen and Reliant™ Cancer Screen, as well as supporting services through Counsyl Complete™, a proprietary suite of solutions, designed to seamlessly integrate Counsyl screening into clinic workflows and patients’ lives.

Search 200,197 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Myriad

Salt Lake City, Utah, United States
Category Company
Founded 1991
Sector Life Science
Employees2,700
Revenue 753M USD (2023)
DESCRIPTION

Myriad is a molecular diagnostic company discovers and commercialize a transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad was founded in 1991 and is based in Salt Lake City, Utah.

DEAL STATS #
Overall 5 of 6
Sector (Life Science) 4 of 5
Type (Add-on Acquisition) 4 of 4
State (California) 2 of 2
Country (United States) 4 of 5
Year (2018) 1 of 1
Size (of disclosed) 1 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-08-03 Assurex Health

Mason, Ohio, United States

Assurex Health, Inc. is an informatics-based precision medicine company providing treatment decision support to healthcare providers for mental health. Assurex Health’s lead product, GeneSight® Psychotropic, evaluates 12 genes known to play a significant role in psychotropic drug response, and utilizing a proprietary combinatorial pharmacogenomics approach called CPGx, assigns patients into one of over 300,000 unique composite phenotypes.

Buy $225M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-04-27 Myriad myPath Melanoma

Salt Lake City, Utah, United States

Myriad myPath Melanoma is a clinically validated GEP test designed to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone.

Sell $33M
Mergr

Product

Company

Legal